Benzinga
25 Feb 2026, 19:30 UTC · 30w ago
Verdict
Headline takes no side. We score LRMR +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Larimar Therapeutics (LRMR) shares surged over 72% on Wednesday, reaching a new 52-week high.
So whatA massive single-day price spike to a new 52-week high indicates an extreme shift in market valuation and strong short-term bullish conviction.
More positive than 99% of claims this week
Citigroup maintained a Buy rating on LRMR and increased its price target from $12 to $14.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 77% of claims this week
Wedbush reaffirmed its Outperform rating for Larimar Therapeutics with a price target of $11.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Stock is surging over 72% following bullish analyst reiterations and price target increases.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
+4.7%
Price agrees with the score
$3.87 vs $3.69 close before publication (Feb 24) · not market-adjusted
LRMR chart →
